Polyspecific antibodies for cancer research
AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies.
The concept of using a molecule with more than one binding site to enhance its biological function has been around for some time. Polyspecific antibodies are the basis of a new class of anti-cancer agents which offer the potential to be directed at multiple tumor antigens to eradicate tumor cells more precisely and effectively.
Polyspecific monoclonal antibodies are genetically engineered proteins that can simultaneously engage two or more different types of epitopes. There are many building block formats to generate BsAbs and TsAbs based on combining the antigen recognition domains of monoclonal antibodies (mAbs).
Bispecific antibodies and trispecific antibodies offer a range of advantages over monoclonal antibodies. This includes that they can redirect specific polyclonal immune cells such as T cells and NK cells to tumor cells to enhance tumor killing, or simultaneously block two different pathways with unique or overlapping functions in pathogenesis. Additionally, BsAbs and TsAbs potentially increase binding specificity by interacting with multiple different cell surface antigens instead of one, as well as reducing development and production costs when compared to multiple single based antibodies used in combination therapy or compared to the production of CAR-T cells.
Pre-clinical studies and early phase clinical trials have demonstrated that bispecific and trispecific antibody therapy offer improved treatment of solid tumor malignancies and highlights the potential they hold for future therapies to come.
For further information on the new range of high quality bispecific and trispecific antibodies please visit https://www.amsbio.com/bispecificandtrispecificantibodies/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / email@example.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery (lentivirus, adenovirus, and adeno-associated virus.
Dr Bill Bradbury, Director, Primetek Solutions (Kingston, UK) ...... On behalf of AMSBIO firstname.lastname@example.org